---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-025814"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:07:58.332720+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports Q2 loss $6.3M; neflamapimod shows 54% risk reduction in DLB extension phase

## Summary
- Net loss of $6.3M for Q2 2025 vs $2.3M loss a year ago; cash $33.5M as of June 30, 2025.
- Phase 2b RewinD-LB extension: neflamapimod reduced risk of clinically significant worsening by 54% (p=0.0037) on CDR-SB at 32 weeks.
- In patients with minimal AD co-pathology (ptau181<2.2), risk reduction improved to 64% (p=0.0001).
- Significant decrease in plasma GFAP biomarker: -18.4 pg/mL from baseline in active group vs +1.1 pg/mL increase in placebo at Week 16.
- Plans to meet FDA in Q4 2025 to align on Phase 3 trial design; Phase 3 initiation mid-2026 subject to funding.

## SEC filing metadata
- accession: 0001437749-25-025814
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774925025814/0001437749-25-025814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774925025814/crvo20250808_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-025814
- JSON: https://secwatch.observer/filing/0001437749-25-025814.json
- Plain text: https://secwatch.observer/filing/0001437749-25-025814.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.